HLB Chairman Jin Yang-gon: 'Open to cooperation with Big Pharma on Repitu's US market'
Predicted impact: Medium· Actual: −4.6% vs sector, volume 0.3× normal (5 trading days)
Liver cancer drug FDA approval hopes and US partnering openness already discussed repeatedly over recent days.